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LETTERS TO THE EDITOR
catheter dysfunction performed during the hemodialysisUrokinase and dialysis therapy
treatment itself. These urokinase protocols hold promise
and are undergoing clinical trials at several centers” [1].To the Editor: In a recent review by Schwab and
Beathard on hemodialysis catheters, the authors did not We believe this continues to accurately reflect the state
of the art. While the study by Twardowski is indeedacknowledge the value of systemic urokinase infusion to
open clotted catheters [1]. Although they admit that the promising [2], we believe further studies should be done
to confirm the safety and efficacy of this procedure priorinfusion appears to be safe and less expensive than either
fibrin sheath stripping or catheter exchange, they also to recommending its wholesale adoption. Multiple con-
firmatory clinical trials were actively underway prior tostate that the “. . . primary disadvantage lies in the fact
that [the infusion] requires four to six hours of hospital the removal of urokinase from the United States market.
Regional Medicare intermediaries exercise broad dis-observation to facilitate payment for the urokinase.”
As a matter of fact, hospitalization for administration cretion in determining appropriate procedures for reim-
bursement. In our areas of practice (North Carolina andof urokinase is not necessary for reimbursement. We have
used urokinase in our outpatient facility for several years Texas), reimbursement for high-dose urokinase per-
formed as an infusion during the hemodialysis treatmentand recently published our experience [2]. Our protocol
uses two to three hours of infusion of 250,000 IU of uroki- in an outpatient hemodialysis facility had not been ap-
proved. The question is at the current state moot, be-nase during outpatient hemodialysis. Heparin is used
together with urokinase. In addition, the method is less cause there appears to be little likelihood that urokinase
in its present form will return to the North Americanexpensive than catheter stripping or replacement. A ma-
jor advantage of the method is that the patient does not market in the near future. We acknowledge the impor-
tance of thrombolytic therapy applied in the dialysis unitmiss dialysis treatment because blood flow is usually
restored. The patient thus avoids hospitalization and the as opposed to any therapy performed in the hospital.
Indeed, confirmatory studies of Dr. Twardowski’s origi-inconvenience related thereto. Outpatient urokinase is
reimbursed in our region (revenue code # 636, HCPCS nal observation were underway at both of our institutions
prior to withdrawal of urokinase from the North Ameri-#J3367), and there is no reason for the lack of reimburse-
ment in other regions, as the method saves money. can market.
Unfortunately, Abbott Laboratories, Inc. (North Chi- Steve J. Schwab and Gerald Beathard
Duke Medical Center, Durham, North Carolina, USAcago, IL, USA), the only manufacturer of urokinase, has
difficulty in providing a sufficient amount of the drug at
REFERENCESpresent. Hopefully, these difficulties are only temporary
and urokinase may be used on an outpatient basis in the 1. Schwab SJ, Beathard G: The hemodialysis catheter conundrum:
We hate them we cannot live without them. Kidney Int 56:1–17, 1999near future.
2. Twardowski ZJ: High-dose intradialytic urokinase to restore the
Zbylut J. Twardowski patency of permanent central vein hemodialysis catheters. Am J
University of Missouri, Columbia, Missouri, USA Kidney Dis 31:841–847, 1998
Correspondence to Zbylut J. Twardowski, M.D., Ph.D., Division of
Nephrology, Department of Medicine, University of Missouri, Colum-
bia, Dialysis Clinic Inc., 3300 LeMone Blvd, Columbia, MO 65201,
USA. Histologic characteristics
REFERENCES of sternoclavicular
1. Schwab SJ, Beathard G: The hemodialysis catheter conundrum:
We hate them we cannot live without them. Kidney Int 56:1–17, 1999 b2-microglobulin amyloidosis2. Twardowski ZJ: High-dose intradialytic urokinase to restore the
patency of permanent central vein hemodialysis catheters. Am J To the Editor: We have read with interest the studyKidney Dis 31:841–847, 1998
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the authors propose a staging for amyloidosis based onReply from the authors
immunoperoxidase staining and on the analysis of clini-In response to Dr. Twardowski’s concern, we quote
cal data. The authors, although aware of the cross-sec-directly from our review. “Recently, Twardowski has
tional design, concluded that macrophages are not re-reported a series of high-dose urokinase infusions for
quired to form amyloid fibrils [1], supporting the view
that macrophage infiltration is a secondary phenomenon.
We drew a similar conclusion based on an ultrastructural 2000 by the International Society of Nephrology
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analysis of b2-microglobulin amyloid deposits identifying its in close relation with the vascular space as it is ob-
the intracellular location of amyloid fibrils [2]. We found served in many other types of amyloidosis? Where does
that intracellular b2-microglobulin amyloid fibrils were b2-microglobulin come from, as there is no b2-microglob-
almost exclusively observed in lysosomes, and there was ulin in the perivascular regions? Do amyloid deposits
no positive b2-microglobulin immunogold labeling of the exclusively arise from b2-microglobulin locally shed from
synthesis machinery of the cell, suggesting that macro- chondrocytes? Supplementary clinical, ultrastructural as
phages are not at the origin of amyloid fibrils but proba- well as biochemical studies will hopefully answer these
bly accumulate as a consequence of amyloidosis [2]. and many other questions on the pathogenesis of dial-
However, our studies also showed a wide variability in ysis-related amyloidosis.
the number of cells in different sections of a given de-
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[3]. Although Garbar et al quoted our work as proposing
Reply from the authorsa role for macrophages in the genesis of Ab2M, we have
never been convinced of this point. Actually, we con- Argile´s and Mourad provide additional evidence that
cluded in that paper that, “Although much progress has macrophages are late actors in b2-microglobulin amy-
been achieved recently with the in vitro formation of loidosis (Ab2M). In their elegant immunoelectronmi-
amyloid fibrils with mononuclear cells, whether macro- croscopy study they evaluated carpal tunnel tissue sam-
phages are at the origin of this condition, or their pres- ples obtained at a late, clinically symptomatic stage [1].
ence is a consequence of it, remains to be elucidated.” Their data suggest that Ab2M deposits are actually
Our subsequent work [2] and the paper of Garbar et al phagocytized rather than synthesized by macrophages.
[1] support the hypothesis that macrophage infiltration In our study we were able to witness early stages of
is a secondary phenomenon. However, as always, should Ab2M deposition [2]. Both the fact that b2-microglobulinthis hypothesis be verified, additional questions will have amyloid was restricted to the surface of an avascular
to be answered. The first one concerns the timing of
tissue, the cartilage, and that the macrophages were ab-
the steps in the genesis of amyloidosis. Garbar et al
sent, led to the identical conclusion, that is that the pres-commented that AGEP modification of b2-microglobulin ence of macrophages is not a prerequisite for b2-micro-would attract macrophages. However, advanced glyca-
globulin amyloid formation.tion of b2-microglobulin has been proposed to be at the
Our description of three stages in Ab2M depositionorigin of amyloidosis, and macrophage infiltration would
applies only to the sternoclavicular joint. Its extensionbe a late phenomenon, only observed in stages II and
to carpal tunnel deposits is as yet unwarranted.III. Why is there such a big delay (measurable in years
Advanced glycation of b2-microglobulin might not betime) between glycation of b2-microglobulin and macro-
a prerequisite to the formation of b2M fibrils. It mightphage recruitment? Second, how can one explain that
be a late phenomenon whose extension, on previousamyloid fibrils are first deposited in an avascular tissue?
Ab2M deposits, might then reach a critical level andWouldn’t one expect to find the very first amyloid depos-
attract macrophages by chemotaxis. b2-microglobulin is
present in the joint fluid at a concentration similar to
that observed in serum [3], and might thus contribute
to amyloid formation on the cartilage independently of
chondrocytes. The mechanism of amyloid formation re- 2000 by the International Society of Nephrology
